As part of the clinical trial, Jordyn Bugarin regularly traveled to Vanderbilt Health, navigating a complex study while living with a disease that can flare unpredictably and permanently limit movement. The experimental drug received federal approval Aug. 19.

Keady has been appointed inaugural Chief Nurse Executive at Mass General Brigham and will depart Vanderbilt Health in October. Pat Givens, DHA, RN, NEA-BC, will provide interim executive nursing leadership across the Vanderbilt Health system.

It only takes 10 minutes for the temperature inside a vehicle to rise 19 degrees and continue to rise. Even on cooler days closer to 70 degrees, children can experience vehicular heatstroke.

Team lands award for expanding access points, streamlining processes and connecting patients to infusion care closer to home.

The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.

The award will be presented Oct. 10 during the American Heart Association’s Hypertension Scientific Session in Arlington, Virginia.

The symposium is free and open to people affected by neurofibromatosis and schwannomatosis, as well as their families, loved ones and caregivers.